In the first part of this study the availability of folinic acid (FA) and its main active circulating metabolite, 5-methyltetrahydrofolate (5-MTHF), were studied in plasma and cerebrospinal fluid (CSF) from normal subjects after i.v. administration of 100 and 250mg of FA. 5-MTHF rapidly appeared in plasma, the maximum value being reached at the first observation time point (1 h 
This finding suggested possible accumulation of 5-MTHF in CSF during repeated administration of FA combined with medium or high dose MTX. In the second part of the study, dealing with a group of eight children treated by such protocols, an increase in CSF 5-MTHF was detected from cycle to cycle in five (r=0.91, P<0.01) with a maximum at 5 x 10-8 M. This progressive accumulation of 5-MTHF in CSF may have a negative effect on the local action of MTX and should be taken into account for therapeutic strategies designed for the management of meningeal leukaemia.
Central nervous system (CNS) involvement remains a critical problem in the therapeutic management of malignant nonHodgkin's lymphomas (Mackintosh et al., 1982) and acute lymphoblastic leukaemia (Duttera et al., 1973) . Chemotherapy using methotrexate (MTX), associated (Freeman et al., 1983) or not (Balis et al., 1985) with intrathecal injections, may be effective in eradicating or preventing meningeal diseases. High dose MTX is increasingly used in place of radiotherapy (Brouwers et al., 1987) , particularly for preventive purposes. MTX concentrations in cerebrospinal fluid (CSF) are critical: abnormally high levels are associated with leukoencephalopathy (Allen et al., 1980) while low concentrations (below a threshold of 10-6 M) are thought to be ineffective (Hryniuk & Bertino, 1969) . Folinic acid (FA), the antidote of MTX, is classically given in conjunction with medium or high-dose MTX; its administration is repeated until the blood MTX level drops below 10-8 M (Bertino, 1981) .
Information on the behaviour of FA and its active metabolite 5-methyltetrahydrofolate (5-MTHF) in CSF is necessary for evaluation of (i) the potential effects of FA rescue in CSF for a given systemic dose of this antidote and, particularly, (ii) the possibility of adverse accumulation of FA and/or 5-MTHF in CSF, which might inhibit MTX cytotoxic effects in CSF during MTX cycles with relatively short intervals. Straw et al. (1984) reported on the plasma pharmacokinetics of FA and 5-MTHF for doses between 25 and 100 mg. In the first part of the present study we evaluated the pharmacokinetics of FA and 5-MTHF in both plasma and CSF for healthy subjects in a higher dose range (100-250 mg). Combined with the findings of Straw et al. (1984) , our study covers the FA dose range generally prescribed to patients (Jolivet et al., 1983) . For obvious ethical and technical reasons repeated lumbar punctures are not possible on patients. Therefore healthy consenting adults were included with one FA dose and one CSF sampling time per subject. Several subjects were thus tested for each concentration-time point in order to obtain representative mean concentration-time points.
The demonstration of a prolonged retention of 5-MTHF in CSF led us to pursue these investigations by determining, Correspondence: G. Milano. Received 8 November, 1988. in the second part of the study, the reduced folate levels in CSF for a group of eight children with acute lymphocytic leukaemia treated by MTX plus FA rescue. It consisted of eight patients (six males and two females) with acute lymphocytic leukaemia, mean age 5 years (2-9), without signs of meningeal disease. They were treated by MTX (2.5 gm-2) and FA rescue according to the EORTC Children's Leukaemia Cooperative group protocol which follows the general guidelines of the BFM protocol (Riehm et al., 1980) . CSF samples were obtained 8 h after the beginning of the 24-h administration of MTX and just before injection of the intrathecal MTX dose. Courses were administered at a 2-week interval. CSF (1-2ml) and blood (3-5 ml) were collected in EDTA tubes. Ascorbic acid (2mgml-1) was added immediately to stabilise the samples.
Materials and methods

Study population
Blood was centrifuged for 10 min at 2,500 r.p.m. Plasma and CSF were stored at -20°C until analysed.
FA and 5-MTHF analysis Stock solutions (10-3 M in saline) were prepared for FA (Specia, France), 5-MTHF (Sigma, France) and the internal standard (IS): paraaminoacetophenone (10-3 M in methanol, Sigma). They were stored at -20°C. An original method based on the extraction procedure was developed. Briefly, 1 ml CSF or plasma (patients or blanks spiked with known amounts of FA, 5-MTHF and IS) was eluted through an extraction cartridge (Sep-Pak C18, Millipore, Waters, France) activated by successive passages of 2 ml methanol, 2 ml H20, and 3 ml Tris 0.1 M, pH = 7.00. Between 1 x 10-7 M and 2.5 x 10-M, peak heights increased linearly with the concentration (r = 0.99 for both FA and 5-MTHF). Intra-assay reproducibility (n=6) was 5% for FA and 10% for 5-MTHF; inter-assay reproducibility (n=6) was 8% for FA and 12% for 5-MTHF. The limit of sensitivity was 1 X 10-8 M (noise x 3, 1 x 10-3 DO full scale) in plasma and CSF for both FA and 5-MTHF. Figure 1 shows the respective time-concentration profiles (unchanged FA and its active metabolite 5-MTHF) for the two FA i.v. doses studied. 5-MTHF quickly appears in plasma, reaching maximal value at the first observation point (1 h). In plasma, FA is cleared more slowly than 5-MTHF; FA was never detected in CSF. 5-MTHF was present in this biological fluid: the maximum concentration was noted 6 h after systemic administration of FA. 5-MTHF was eliminated more slowly from CSF than from plasma.
Results
The effects of increasing FA doses on pharmacokinetic parameters are shown in Table I . The clearance and elimination half-life of FA were not particularly modified by the FA dose. The AUC of FA in plasma and 5-MTHF in both plasma and CSF rose proportionally to the FA dose. The AUC ratios for 100 and 250mg were respectively 0.13 and 0.15 between 5-MTHF and FA in plasma, 0.07 and 0.09 for 5-MTHF between CSF and plasma, and 0.009 and 0.013 between 5-MTHF in LCR and FA in plasma. For all folates (FA plus 5-MTHF), the ratios between CSF and plasma were 0.008 for 100mg and 0.012 for 250mg. (Jolivet et al., 1983) . Both in vitro investigations (Browman lues. 0, FA in plasma; and pharmacokinetic studies on FA are required CSF.
to obtain such information. CNS involvement in non-I Hodgkin's lymphoma and acute lymphocytic leukaemia may be prevented or treated by repeated medium or high dose MTX combined with FA rescue (Freeman et al., 1983; Balis et al., 1985) . Data were missing on the possibility of an adverse accumulation of FA in CSF in such protocols; in addition, as dihydrofolate reductase is present in the brain (Pollock & Kaufman, 1978) , information is required on the appropriate systemic FA dose for neutralisation of excessive MTX exposure in CSF (Cohen et al., 1986) . The findings of the present study may help to clarify these points. The improved analytical method we used allows rapid, specific and sensitive measurement of FA and its main circulating metabolite in plasma and CSF. The kinetics of stereoisomers of unchanged FA has been dealt with by Straw et al. (1984) but is not central in this work and, moreover, 5-MTHF is not compromised by this stereochemistry. In light of the findings of a previous study (Payet et al., 1987) , FA kinetics appear to be the same in both cancer patients and healthy volunteers, making extrapolation of the present results obtained in healthy subjects to cancer patients under MTX treatment acceptable. The values of the main pharmacokinetic parameters determined in the first part of the study for FA and 5-MTHF closely agree with those reported by the previously mentioned authors. 5-MTHF appears rapidly in plasma, the maximum value occurring at the initial time point (1 h). Results agree with previous reports of maximum plasma FA concentration at 1 h (Hamel et al., 1981) or 1-2 h (Payet et al., 1987) . In the present study FA was eliminated in plasma more slowly than 5-MTHF. In healthy volunteers, Payet et al. (1987) noted terminal half-lives of 7.0 and 1.9h for FA and 5-MTHF respectively during a 12 h post-injection period. Herein, during a 24h survey period, the difference between the slopes of elimination of these two products was more marked: 5-MTHF half-life was 3-4 times shorter than that of FA. The two FA doses studied (100 and 250 mg) did not modify the pharmacokinetic parameters of FA and 5-MTHF in plasma and CSF. This is strengthened by the AUC rise in parallel to the dose (Table I) . FA kinetics thus appear linear between 100 and 250 mg. This information complements similar data on FA linearity between 25 and 100mg (Straw et al., 1984) . 5-MTHF was the only folate detectable in CSF during systemic administration of FA (Mehta et al., 1979 ). It appears clearly that only 5-MTHF reaches the CSF (Figure 1 ). In cases of acute neurological dysfunction due to high-dose MTX (Packer et al., 1983) , specific MTX CNS rescue would probably be best achieved by using the stable preparation of 5-MTHF now available (Reggev & Djerassi, 1986) . When classical rescue by FA is used, oral administration would also appear better indicated because 5-MTHF is more bioavailable by this route than after i.m. or i.v. administration (McGuire et al., 1986) . For all folates considered together (FA plus 5-MTHF) the AUC ratios between CSF and plasma were approximately 1%. This value is comparable to the passage of MTX from plasma to CSF that other authors (Borsi & Moe, 1987) and ourselves (Thyss et al., 1987) have established as being very close to 1%. But disappearance of MTX from CSF is much more rapid (6.6 h: Bode et al., 1980) than that found herein for 5-MTHF. Consequently, and this is the central point of this work, during repeated sequential administrations of FA, 5-MTHF might accumulate in CSF, the potential risk being an inhibition of further MTX '.-tion in this compartment. This hypothetical situation might be encountered during administration of chemotherapy for childhood ALL using MTX plus FA rescue (Riehm et al., 1980) with repeated courses at short-term intervals. We thus checked the evolution of CSF folates in a limited series of eight children treated by a similar protocol. None of them had a meningeal involvement with their disease. The absence of detectable unchanged FA in CSF in healthy subjects has been confirmed in these patients. Levels of 5-MTHF were detectable for 7/8 patients. For five of them CSF 5-MTHF concentrations increased during treatment courses (up to 5 x 10-8 M). Standard doses (0.5 gm-2) and high doses (2.5 gm-2) of MTX generate median MTX CSF values of 8 x 10-8 M and 6 x I0 -7 M respectively (Thyss et al., 1987) . Diddens et al. (1987) established in a lymphoblastoid cell line that the cytotoxic effect of high concentrations of MTX was reversed by relatively low concentrations of simultaneously added leucovorin. There is thus a potential risk of competition between folates and antifolates in CSF during standard or even high dose MTX plus FA rescue in the treatment of childhood ALL. The time-concentration profile of 5-MTHF in CSF should certainly be explored in a larger series of patients in view to strengthen our present conclusions.
These results should allow clinicians to be aware of the possibility of 5-MTHF accumulation in CSF and may lead them to reconsider the design of therapy strategy in terms of FA doses and duration of administration in order to improve the management of meningeal leukaemia by MTX.
